CoChat
Sign Up
Cited by 24Cervical Cancer and HPV ResearchWomen's cancer prevention and managementReproductive tract infections research

Addressing global disparities in cervical cancer burden: a narrative review of emerging strategies

Open access
Gopalkrishnan, Kalpana, Karim, Roksana·2025·Current HIV/AIDS Reports
DOI 10.1007/s11904-025-00727-2PMC PMC11842523
Open this paper in CoChat — free accountOpen PDF

Abstract

Purpose of Review: Cervical cancer burden is disproportionately higher in low to middle income countries, especially in countries with a high human immunodeficiency virus (HIV) burden. This review investigates barriers to implementation and assesses current progress in cervical cancer screening in lower resource settings by reviewing technologies and strategies that have already been implemented in low to middle income countries. Recent Findings: Several novel innovations embrace the recent World Health Organization (WHO) update to screening guidelines that recommends a “screen and treat” approach rather than a “screen, triage and treat” approach. Innovations include human papillomavirus (HPV) self-sampling, portable cervical visualization devices, and creative large-scale approaches to increase screening accessibility. Summary: Overall, a low-cost, accurate, point-of-care screening test could alleviate most of the barriers associated with cervical cancer screening in lower resource settings. Further research into the development of a low-cost HPV test in conjunction with the HPV vaccine and other screening tools could expedite progress.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11904-025-00727-2

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 53

  1. [1]Singh D, Vignat J, Lorenzoni V, Eslahi M, Ginsburg O, Lauby-Secretan B, et al. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Global Health. 2023;11(2):e197–206. 36528031 PMC9848409 · DOI · Paper page
  2. [5]Asangbeh-Kerman SL, Davidović M, Taghavi K, Kachingwe J, Rammipi KM, Muzingwani L et al. Cervical cancer prevention in countries with the highest HIV prevalence: a review of policies. BMC Public Health. 2022;22(1). PMC9367081 35948944
  3. [6]Gossa W, Fetters M. How Should Cervical Cancer Prevention Be Improved in LMICs? 2020. 32048583
  4. [7]Almonte M, Ilbawi AM, Maza M, Saville M, Murillo R, Forestier M et al. From commitments to action: the first global cervical cancer elimination forum. Lancet Reg Health– Americas. 2024;36. PMC11225856 38974379
  5. [8]eClinicalMedicine. Global strategy to eliminate cervical cancer as a public health problem: are we on track? eClinicalMedicine. 2023;55. PMC9874313 36712891
  6. [9]Wentzensen N, Clarke MA, Perkins RB. Impact of COVID-19 on cervical cancer screening: challenges and opportunities to improving resilience and reduce disparities. Prev Med. 2021;151:106596. 34217415 PMC8241689 · DOI
  7. [10]Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, et al. HPV screening for cervical cancer in rural India. N Engl J Med. 2009;360(14):1385–94. 19339719 · DOI · Paper page
  8. [11]Lohiya A, Daniel RA, Kumar D, Varghese C, Rath RS. Effectiveness of visual inspection with Acetic Acid (VIA) Screening on Cervical Cancer Mortality and incidence - A systematic review and Meta-analysis. Asian Pac J Cancer Prev. 2022;23(2):399–407. 35225450 PMC9272618 · DOI
  9. [13]Perkins RB, Guido RL, Saraiya M, Sawaya GF, Wentzensen N, Schiffman M, et al. Summary of current guidelines for cervical Cancer screening and management of abnormal test results: 2016–2020. J Womens Health (Larchmt). 2021;30(1):5–13. 33464997 PMC8020523 · DOI
  10. [15]Wang W, Arcà E, Sinha A, Hartl K, Houwing N, Kothari S. Cervical cancer screening guidelines and screening practices in 11 countries: a systematic literature review. Prev Med Rep. 2022;28:101813. 35637896 PMC9142642 · DOI
  11. [17]WHO guideline for screening. and treatment of cervical pre-cancer lesions for cervical cancer prevention 2nd ed. Geneva 2021. 34314129
  12. [18]Kuhn L, Saidu R, Boa R, Tergas A, Moodley J, Persing D, et al. Clinical evaluation of modifications to a human papillomavirus assay to optimise its utility for cervical cancer screening in low-resource settings: a diagnostic accuracy study. Lancet Global Health. 2020;8(2):e296–304. 31981559 PMC8720235 · DOI · Paper page
  13. [19]Liu G, Sharma M, Tan N, Barnabas RV. HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer. Aids. 2018;32(6):795–808. 29369827 PMC5854529 · DOI · Paper page
  14. [20]Poli U, Bidinger P, Gowrishankar S. Visual inspection with acetic acid (via) screening program: 7 years experience in early detection of cervical cancer and pre-cancers in rural South India. Indian J Community Med. 2015;40(3):203. 26170547 PMC4478664 · DOI
  15. [21]Gonzalez M, Boonya-Ananta T, Madhivanan P, Ramella-Roman JC. Cervical imaging in the low resource setting: a review. Biosensors. 2022;12(10):786. 36290924 PMC9599850 · DOI
  16. [23]Shastri SS, Mittra I, Mishra GA, Gupta S, Dikshit R, Singh S, et al. Effect of VIA screening by primary health workers: randomized controlled study in Mumbai, India. J Natl Cancer Inst. 2014;106(3):dju009. 24563518 PMC3982783 · DOI
  17. [24]Woo YL, Gravitt P, Khor SK, Ng CW, Saville M. Accelerating action on cervical screening in lower- and middle-income countries (LMICs) post COVID-19 era. Prev Med. 2021;144:106294. 33678225 PMC7931730 · DOI
  18. [26]Alam NE, Islam MS, Rayyan F, Ifa HN, Khabir MIU, Chowdhury K, et al. Lack of knowledge is the leading key for the growing cervical cancer incidents in Bangladesh: a population based, cross-sectional study. PLOS Global Public Health. 2022;2(1):e0000149. 36962139 PMC10021366 · DOI
  19. [27]Petersen Z, Jaca A, Ginindza TG, Maseko G, Takatshana S, Ndlovu P et al. Barriers to uptake of cervical cancer screening services in low-and-middle-income countries: a systematic review. BMC Womens Health. 2022;22(1). PMC9716693 36461001
  20. [28]Isa Modibbo F, Dareng E, Bamisaye P, Jedy-Agba E, Adewole A, Oyeneyin L, et al. Qualitative study of barriers to cervical cancer screening among Nigerian women. BMJ Open. 2016;6(1):e008533. 26754174 PMC4716205 · DOI · Paper page
  21. [29]Srinath A, van Merode F, Rao SV, Pavlova M. Barriers to cervical cancer and breast cancer screening uptake in low- and middle-income countries: a systematic review. Health Policy Plann. 2022;38(4):509–27. PMC10089064 36525529 · DOI
  22. [30]Saei Ghare Naz M, Kariman N, Ebadi A, Ozgoli G, Ghasemi V, Rashidi Fakari F. Educational interventions for Cervical Cancer Screening Behavior of women: a systematic review. Asian Pac J Cancer Prev. 2018;19(4):875–84. 29693331 PMC6031778
  23. [33]Serrano B, Ibáñez R, Robles C, Peremiquel-Trillas P, de Sanjosé S, Bruni L. Worldwide use of HPV self-sampling for cervical cancer screening. Prev Med. 2022;154:106900. 34861338 · DOI
  24. [34]Erik JN, Brandy RM, Travis L, Jessica F, Rebecca G, Lauren DA. The acceptability of self-sampled screening for HPV DNA: a systematic review and meta-analysis. Sex Transm Infect. 2017;93(1):56. 28100761 · DOI · Paper page
  25. [36]Narvaez L, Viviano M, Dickson C, Jeannot E. The acceptability of HPV vaginal self-sampling for cervical cancer screening in Latin America: a systematic review. Public Health Pract. 2023;6:100417. PMC10410574 37564780 · DOI
  26. [37]Vallely AJB, Saville M, Badman SG, Gabuzzi J, Bolnga J, Mola GDL, et al. Point-of-care HPV DNA testing of self-collected specimens and same-day thermal ablation for the early detection and treatment of cervical pre-cancer in women in Papua New Guinea: a prospective, single-arm intervention trial (HPV-STAT). Lancet Global Health. 2022;10(9):e1336–46. 35878625 · DOI
  27. [38]Choi YS, Jin H, Lee KE. Usefulness Analysis of Urine Samples for early screening of human papilloma virus infection. J Cancer Prev. 2019;24(4):240–4. 31950024 PMC6951315 · DOI
  28. [39]Poljak M, Cuschieri K, Alemany L, Vorsters A. Testing for human papillomaviruses in urine, blood, and oral specimens: an update for the laboratory. J Clin Microbiol. 2023;61(8):e0140322. 10.1128/jcm.01403-22. Epub 2023 Jul 13. PMID: 37439692; PMCID: PMC10446865. PMC10446865 37439692 · DOI
  29. [40]Asiedu MN, Agudogo JS, Dotson ME, Skerrett E, Krieger MS, Lam CT et al. A novel speculum-free imaging strategy for visualization of the internal female lower reproductive system. Sci Rep. 2020;10(1). PMC7538883 33024146
  30. [41]Shin MB, Liu G, Mugo N, Garcia PJ, Rao DW, Bayer CJ et al. A Framework for Cervical Cancer Elimination in Low-and-Middle-Income countries: a scoping review and Roadmap for interventions and Research priorities. Front Public Health. 2021;9. PMC8281011 34277540
  31. [42]Pryor RJ, Masroor N, Stevens M, Sanogo K, Hernández O’Hagan PJ, Bearman G. Cervical cancer screening in rural mountainous Honduras: knowledge, attitudes and barriers. Rural Remote Health. 2017;17(2):3820. 28549381 · DOI
  32. [43]Sankaranarayanan R. Screening for cancer in low- and middle-income countries. Ann Glob Health. 2014;80(5):412–7. 25512156 · DOI · Paper page
  33. [44]Sharma J, Yennapu M, Priyanka Y. Screening guidelines and programs for cervical Cancer Control in Countries of different economic groups: a narrative review. Cureus. 2023;15(6):e41098. 37519623 PMC10381098
  34. [45]Uddin A, Sumon MA, Pervin S, Sharmin F. Cervical Cancer in Bangladesh. South Asian J Cancer. 2023;12(1):36–8. 36851938 PMC9966158 · DOI
  35. [46]Gerstl S, Lee L, Nesbitt RC, Mambula C, Sugianto H, Phiri T, et al. Cervical cancer screening coverage and its related knowledge in southern Malawi. BMC Public Health. 2022;22(1):295. 35164716 PMC8842862 · DOI
  36. [47]Wang S, Dang L, Liu S, Rezhake R, Yan H, Duan X, et al. Cervical Cancer Screening via Visual Inspection with Acetic Acid and Lugol Iodine for triage of HPV-Positive women. JAMA Netw Open. 2024;7(3):e244090. 38551562 PMC10980959 · DOI
  37. [48]Teixeira JC, Vale DB, Bragança JF, Campos CS, Discacciati MG, Zeferino LC. Cervical cancer screening program based on primary DNA-HPV testing in a Brazilian city: a cost-effectiveness study protocol. BMC Public Health. 2020;20(1):576. 32345284 PMC7189449 · DOI
  38. [49]Teixeira JC, Vale DB, Campos CS, Polegatto I, Bragança JF, Discacciati MG, et al. Transition from opportunistic cytological to organized screening program with DNA-HPV testing detected prevalent cervical cancers 10 years in advance. Sci Rep. 2024;14(1):20761. 39237756 PMC11377760 · DOI
  39. [50]Allanson ER, Schmeler KM. Cervical Cancer Prevention in Low- and Middle-Income Countries. Clin Obstet Gynecol. 2021;64(3):501–18. 34120126 PMC8324570 · DOI
  40. [51]Yeates KE, Sleeth J, Hopman W, Ginsburg O, Heus K, Andrews L, et al. Evaluation of a smartphone-based training strategy among Health Care workers Screening for Cervical Cancer in Northern Tanzania: the Kilimanjaro Method. J Glob Oncol. 2016;2(6):356–64. 28717721 PMC5493243 · DOI
  41. [52]Asgary R, Cole H, Adongo P, Nwameme A, Maya E, Adu-Amankwah A, et al. Acceptability and implementation challenges of smartphone-based training of community health nurses for visual inspection with acetic acid in Ghana: mHealth and cervical cancer screening. BMJ Open. 2019;9(7):e030528. 31315879 PMC6661590 · DOI
  42. [53]Catarino R. Cervical cancer screening in developing countries at a crossroad: emerging technologies and policy choices. World J Clin Oncol. 2015;6(6):281. 26677441 PMC4675913 · DOI
  43. [54]Agudogo J, Asiedu M, Ramanujam N, Dotson ME. Development and utilization of a novel cervical visualization tool, the Callascope, for home-based self-exams. Gynecol Oncol. 2021;162:S128–9. · DOI
  44. [56]Mueller JL, Asma E, Lam CT, Krieger MS, Gallagher JE, Erkanli A, et al. International Image Concordance Study to compare a point-of-care tampon colposcope with a standard-of-care colposcope. J Lower Genit Tract Dis. 2017;21(2):112–9. PMC5365351 28263237 · DOI
  45. [57]Quinn MK, Bubi TC, Pierce MC, Kayembe MK, Ramogola-Masire D, Richards-Kortum R. High-resolution Microendoscopy for the detection of cervical neoplasia in low-resource settings. PLoS ONE. 2012;7(9):e44924. 23028683 PMC3445555 · DOI
  46. [58]Hunt B, Fregnani J, Schwarz RA, Pantano N, Tesoni S, Possati-Resende JC, et al. Diagnosing cervical neoplasia in rural Brazil using a Mobile Van equipped with in vivo Microscopy: a cluster-Randomized Community Trial. Cancer Prev Res (Phila). 2018;11(6):359–70. 29618459 PMC5984709 · DOI
  47. [59]Xue P, Ng MTA, Qiao Y. The challenges of colposcopy for cervical cancer screening in LMICs and solutions by artificial intelligence. BMC Med. 2020;18(1). PMC7271416 32493320
  48. [60]Hou X, Shen G, Zhou L, Li Y, Wang T, Ma X. Artificial Intelligence in Cervical Cancer Screening and diagnosis. Front Oncol. 2022;12. PMC8963491 35359358
  49. [62]Stelzle D, Tanaka LF, Lee KK, Ibrahim Khalil A, Baussano I, Shah ASV, et al. Estimates of the global burden of cervical cancer associated with HIV. Lancet Global Health. 2021;9(2):e161–9. 33212031 PMC7815633 · DOI
  50. [63]Sigfrid L, Murphy G, Haldane V, Chuah FLH, Ong SE, Cervero-Liceras F, et al. Integrating cervical cancer with HIV healthcare services: a systematic review. PLoS ONE. 2017;12(7):e0181156. 28732037 PMC5521786 · DOI
  51. [64]Guidance Note. Prioritization Framework for Supporting Health and Longevity among people living with HIV [press release]. The Global Fund; 2023.
  52. [65]McCormick LJ, Gutreuter S, Adeoye O, Alger SX, Amado C, Bay Z, et al. Cervical Cancer screening positivity among women living with HIV in CDC-PEPFAR Programs 2018–2022. J Acquir Immune Defic Syndr. 2023;94(4):301–7. 37643419 PMC11289765 · DOI
  53. [68]Ebrahimi N, Yousefi Z, Khosravi G, Malayeri FE, Golabi M, Askarzadeh M et al. Human papillomavirus vaccination in low- and middle-income countries: progression, barriers, and future prospective. Front Immunol. 2023;14. PMC10227716 37261366

Cited by

Sorted by citations

Authors
Gopalkrishnan, K., & Karim, R.
Affiliations
University of Southern California (US)
Corresponding author
Karim, Roksana
ORCID
Karim, Roksana
Venue
Current HIV/AIDS Reports
Publisher
Springer Science and Business Media LLC
Published
2025-02-21
Volume
22
Issue
1
Pages
18-18
ISSN
  • 1548-3568 (ISSN-L)
  • 1548-3576
DOI
10.1007/s11904-025-00727-2
PMC
PMC11842523
OpenAlex
W4407774481
Cited by
24
References
5
Citations by year
2026: 14 · 2025: 10
FWCI
3.69
Type
journal article
Language
en
Open access
Licence
Locations
  • Current HIV/AIDS Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
University of Southern California
Topics
  • Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Women's cancer prevention and management
  • Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
Keywords
cervical cancer, cervical cancer screening, low- and middle-income countries, HIV, HPV self-sampling, point-of-care testing, screen-and-treat, HPV vaccine, global health disparities
MeSH terms
Uterine Cervical Neoplasms, Developing Countries, Female, Humans, Mass Screening, Global Health, HIV Infections, Papillomavirus Infections, Papillomavirus Vaccines, Healthcare Disparities, Early Detection of Cancer

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review